Chardan Capital Markets initiated coverage on Vascular Biogenics with a new price target

4/28/22 6:17:44 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Chardan Capital Markets initiated coverage of Vascular Biogenics with a rating of Buy and set a new price target of $5.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VBLT

Date	Price Target	Rating	Analyst
7/20/2022		Outperform → Perform	Oppenheimer
7/20/2022		Buy → Neutral	H.C. Wainwright
7/18/2022	$5.50	Outperform	Oppenheimer
4/28/2022	$5.00	Buy	Chardan Capital Markets